Rare Cancers Australia and the National Oncology Alliance (NOA) are working to improve equitable access to the best cancer care and emerging cancer treatments and technologies. Genomic sequencing technology has enabled new frontiers of cancer research, drug discovery, and clinical care by offering the potential for precise and personalised approaches to cancer treatment. This is especially relevant for patients with rare cancers, who suffer from limited access to new targeted cancer treatments that offer hope for improved chances of survival.
Genomic Testing Blueprint
This report seeks to characterise the cancer genomics landscape in Australia and explore the salient considerations around defining a path towards broad funded genomic testing for cancer patients.